JP2016533392A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016533392A5 JP2016533392A5 JP2016545265A JP2016545265A JP2016533392A5 JP 2016533392 A5 JP2016533392 A5 JP 2016533392A5 JP 2016545265 A JP2016545265 A JP 2016545265A JP 2016545265 A JP2016545265 A JP 2016545265A JP 2016533392 A5 JP2016533392 A5 JP 2016533392A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- disease
- lys
- arg
- ald
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 208000024827 Alzheimer disease Diseases 0.000 claims 6
- 206010012239 Delusion Diseases 0.000 claims 6
- 230000001149 cognitive effect Effects 0.000 claims 6
- 231100000868 delusion Toxicity 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 3
- 208000000044 Amnesia Diseases 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 3
- 208000026139 Memory disease Diseases 0.000 claims 3
- 206010027951 Mood swings Diseases 0.000 claims 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 3
- 230000016571 aggressive behavior Effects 0.000 claims 3
- 230000007423 decrease Effects 0.000 claims 3
- 230000006984 memory degeneration Effects 0.000 claims 3
- 208000023060 memory loss Diseases 0.000 claims 3
- 230000003252 repetitive effect Effects 0.000 claims 3
- 230000035807 sensation Effects 0.000 claims 3
- 208000019116 sleep disease Diseases 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 229940095064 tartrate Drugs 0.000 claims 3
- 230000000007 visual effect Effects 0.000 claims 3
- 230000001755 vocal effect Effects 0.000 claims 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 2
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 201000008319 inclusion body myositis Diseases 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 231100000419 toxicity Toxicity 0.000 claims 2
- 230000001988 toxicity Effects 0.000 claims 2
- 102000004020 Oxygenases Human genes 0.000 claims 1
- 108090000417 Oxygenases Proteins 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361884722P | 2013-09-30 | 2013-09-30 | |
| US61/884,722 | 2013-09-30 | ||
| PCT/US2014/058049 WO2015048647A1 (en) | 2013-09-30 | 2014-09-29 | Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018210325A Division JP2019052158A (ja) | 2013-09-30 | 2018-11-08 | カルジオリピン標的化ペプチドはベータアミロイドオリゴマー毒性を阻害する |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016533392A JP2016533392A (ja) | 2016-10-27 |
| JP2016533392A5 true JP2016533392A5 (https=) | 2017-11-09 |
| JP6434523B2 JP6434523B2 (ja) | 2018-12-05 |
Family
ID=52744565
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016545265A Expired - Fee Related JP6434523B2 (ja) | 2013-09-30 | 2014-09-29 | カルジオリピン標的化ペプチドはベータアミロイドオリゴマー毒性を阻害する |
| JP2018210325A Withdrawn JP2019052158A (ja) | 2013-09-30 | 2018-11-08 | カルジオリピン標的化ペプチドはベータアミロイドオリゴマー毒性を阻害する |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018210325A Withdrawn JP2019052158A (ja) | 2013-09-30 | 2018-11-08 | カルジオリピン標的化ペプチドはベータアミロイドオリゴマー毒性を阻害する |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160375088A1 (https=) |
| EP (1) | EP3052115A4 (https=) |
| JP (2) | JP6434523B2 (https=) |
| CN (1) | CN106163537A (https=) |
| AU (2) | AU2014324580B2 (https=) |
| CA (1) | CA2925757A1 (https=) |
| WO (1) | WO2015048647A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3052115A4 (en) * | 2013-09-30 | 2017-09-27 | Cornell University | Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity |
| WO2015095077A1 (en) * | 2013-12-16 | 2015-06-25 | Cornell University | Methods and compositions for treating and preventing cognitive dysfunction |
| CA3020393A1 (en) * | 2016-04-11 | 2017-10-19 | Carnot, Llc | Chiral peptides |
| CN107320711A (zh) * | 2017-03-24 | 2017-11-07 | 南京大学 | 化合物ss‑31在制备治疗弗里德赖希共济失调及相关疾病药物中的应用 |
| AU2020368789B2 (en) * | 2019-10-16 | 2024-01-18 | Naturesense Co., Ltd. | Peptide for improving memory and preventing or alleviating cognitive impairment, composition containing same and preparation method therefor |
| CN117881411A (zh) | 2021-06-01 | 2024-04-12 | 艾迪雅生物有限责任公司 | 用于眼部药物的延长释放药物递送系统和使用方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1307219A4 (en) * | 1999-08-13 | 2005-04-06 | Univ Columbia | METHODS OF INHIBITING BETA FIBRILLE BINDING BETA TO RAGE RECEPTOR, AND CONSEQUENCES THEREOF |
| CN101440124B (zh) * | 2003-02-04 | 2012-07-18 | 科内尔研究基金会 | 用于防止线粒体通透性改变的方法 |
| SI2656854T1 (sl) * | 2003-02-04 | 2015-09-30 | Cornell Research Foundation, Inc. | Uporabe aromatsko-kationskega peptida |
| CA2851972C (en) * | 2004-01-23 | 2015-06-23 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
| CA2947335A1 (en) * | 2005-09-16 | 2007-03-29 | Cornell Research Foundation, Inc. | Methods for reducing cd36 expression |
| AU2012271691A1 (en) * | 2011-06-14 | 2014-01-16 | Stealth Peptides International, Inc. | Aromatic-cationic peptides and uses of same |
| EP3052115A4 (en) * | 2013-09-30 | 2017-09-27 | Cornell University | Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity |
-
2014
- 2014-09-29 EP EP14848640.0A patent/EP3052115A4/en not_active Withdrawn
- 2014-09-29 JP JP2016545265A patent/JP6434523B2/ja not_active Expired - Fee Related
- 2014-09-29 AU AU2014324580A patent/AU2014324580B2/en not_active Ceased
- 2014-09-29 CN CN201480063400.5A patent/CN106163537A/zh active Pending
- 2014-09-29 WO PCT/US2014/058049 patent/WO2015048647A1/en not_active Ceased
- 2014-09-29 CA CA2925757A patent/CA2925757A1/en not_active Abandoned
- 2014-09-29 US US15/025,612 patent/US20160375088A1/en not_active Abandoned
-
2018
- 2018-11-08 JP JP2018210325A patent/JP2019052158A/ja not_active Withdrawn
-
2020
- 2020-05-25 AU AU2020203424A patent/AU2020203424A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016533392A5 (https=) | ||
| ES2337700T3 (es) | Terapia combinada de agonista de dopamina con sedantes para mejorar la calidad del sueño. | |
| FI3562486T3 (fi) | Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa | |
| WO2013188210A3 (en) | Treatment of side effects associated with parkinson's disease treatments | |
| BR112014027010A2 (pt) | uso de laquinimod de alta dose para tratamento de esclerose múltipla | |
| JP2017506624A5 (https=) | ||
| PH12014500472A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| CA2869599C (en) | Compounds which inhibit neuronal exocytosis (ii) | |
| ES2663680T3 (es) | Composiciones que comprenden vortioxetina y donepezilo | |
| JP2019532926A5 (https=) | ||
| TW201613591A (en) | Pharmaceutical compositions comprising a DEXTROMETHORPHAN compound and QUINIDINE for the treatment of agitation in dementia | |
| PH12017502049A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2017535612A5 (https=) | ||
| JP2007505139A5 (https=) | ||
| JP2013533287A5 (https=) | ||
| JP2014050390A5 (https=) | ||
| JP2013544245A5 (ja) | ネプリライシンの発現および活性を増大させるための医薬組成物 | |
| JP2020524689A5 (https=) | ||
| RU2007125589A (ru) | Способ улучшения структуры и/или функций артериол, активный агент для улучшения структуры и/или функций артериол и набор для лечения состояний, характеризующихся ненормальной структурой или функцией артериол | |
| JP2008110970A5 (https=) | ||
| JP2018521086A5 (https=) | ||
| JP2016533346A5 (https=) | ||
| JP2013543004A5 (https=) | ||
| JP2018505218A5 (https=) | ||
| CN102266312A (zh) | 替普瑞酮在制备预防和/或治疗阿片类毒品成瘾药物中的应用 |